Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CEO Sells 22,500 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric Dube sold 22,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $43.95, for a total value of $988,875.00. Following the completion of the sale, the chief executive officer directly owned 432,886 shares of the company’s stock, valued at approximately $19,025,339.70. This represents a 4.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Trading Down 0.2%

TVTX stock traded down $0.10 during midday trading on Wednesday, hitting $44.70. The company had a trading volume of 2,390,035 shares, compared to its average volume of 2,890,153. The company has a current ratio of 3.13, a quick ratio of 2.70 and a debt-to-equity ratio of 3.16. Travere Therapeutics, Inc. has a 52 week low of $13.88 and a 52 week high of $48.61. The stock’s 50 day moving average price is $32.59 and its 200 day moving average price is $32.83. The stock has a market cap of $4.16 billion, a price-to-earnings ratio of -194.33 and a beta of 1.13.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings data on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.29. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The firm had revenue of $127.20 million during the quarter, compared to the consensus estimate of $136.23 million. During the same quarter in the previous year, the company posted ($0.47) earnings per share. The business’s revenue was up 55.6% on a year-over-year basis. As a group, equities research analysts expect that Travere Therapeutics, Inc. will post -0.16 earnings per share for the current fiscal year.

Travere Therapeutics News Roundup

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target from $45 to $60 and kept a “buy” rating, implying meaningful upside vs. current levels — a bullish signal from a major sell‑side shop. TD Cowen price target raise
• Positive Sentiment: Wells Fargo upgraded its target to $50 and assigned an “overweight” rating, another near‑term positive catalyst supporting higher valuation expectations. Wells Fargo price target raise
• Neutral Sentiment: HC Wainwright reiterated a “Buy” and $57 target but trimmed FY2027–FY2030 EPS forecasts slightly (e.g., FY2027 cut from $0.71 to $0.60; FY2030 to $4.59 from $4.61). The firm still models substantial multi‑year growth, so this is more of a modest forecast tweak than a change in conviction. HC Wainwright note
• Neutral Sentiment: Earnings call transcript for Q1 2026 is available — recall Travere reported a year‑over‑year revenue gain and an EPS beat in the quarter, which helped underpin recent analyst upgrades. Review the transcript for management commentary on sparsentan commercialization and margin trajectory. Q1 2026 earnings transcript
• Negative Sentiment: Director Roy Baynes sold 9,750 shares (about $431k at the sale price) under a pre‑arranged Rule 10b5‑1 plan. Insider sales can be perceived negatively by the market despite the trading plan disclosure; monitor for any further insider activity. Insider sale filing

Analyst Ratings Changes

Several analysts have weighed in on TVTX shares. HC Wainwright boosted their price objective on Travere Therapeutics from $47.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday. Wedbush boosted their price objective on Travere Therapeutics from $53.00 to $55.00 and gave the company an “outperform” rating in a research report on Tuesday. TD Cowen upped their target price on Travere Therapeutics from $45.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday. Wall Street Zen downgraded Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Citigroup upped their target price on Travere Therapeutics from $53.00 to $59.00 and gave the company a “buy” rating in a report on Tuesday. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Travere Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $47.83.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Stephens Investment Management Group LLC bought a new position in Travere Therapeutics in the third quarter worth $38,232,000. State Street Corp raised its holdings in Travere Therapeutics by 47.8% in the fourth quarter. State Street Corp now owns 4,756,666 shares of the company’s stock worth $181,752,000 after purchasing an additional 1,538,827 shares in the last quarter. Wellington Management Group LLP raised its holdings in Travere Therapeutics by 3,331.9% in the third quarter. Wellington Management Group LLP now owns 1,201,469 shares of the company’s stock worth $28,715,000 after purchasing an additional 1,166,460 shares in the last quarter. Fiera Capital Corp bought a new position in Travere Therapeutics in the fourth quarter worth $33,398,000. Finally, Perceptive Advisors LLC bought a new position in Travere Therapeutics in the second quarter worth $12,347,000.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.